Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab adjunctive therapy for Burkitt's lymphoma
ISRCTN90296187Phase 2Completed
- Sponsor
- Kamuzu University of Health Sciences
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab in Burkitt lymphoma (BL) (3 arms), sponsored by Kamuzu University of Health Sciences. Primary endpoint: Clinical Complete Remission rate at end of chemotherapy. Started Jun 2016; status: completed.
02
Drugs
rituximab
03
Conditions
Burkitt lymphoma (BL)
Beyond the preview
Go deeper on ISRCTN90296187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN90296187.